Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/58057
Title: Real-life experience with entrectinib in neurotrophic tyrosine receptor kinase fusion-positive solid tumors: a multicenter retrospective trial
Authors: Yilmaz, Feride
Yasar, Serkan
Mandel, Nil Molinas
Kacan, Turgut
Ozdemir, Melek
Dogu, Gamze Gokoz
Şengül, Nilay
Meydan, Nezih
Başal, Fatma Buğdaycı
Tolunay, Pınar Kubilay
Hamamcı, Melda Berber
Dinçer, Oğuz Salih
Bahçeci, Aykut
Özer, Leyla
Ajredini, Miraç
Kırca, Önder
Yersal, Özlem
Can, Orçun
Günaldı, Meral
Demir, Gökhan
Yalçın, Şuayib
Keywords: [No abstract available]
Analog Secretory Carcinoma
Safety
Publisher: Springer
Abstract: BackgroundNeurotrophic tyrosine receptor kinase (NTRK) gene fusions represent rare somatic mutations in many types of cancer and have enabled the use of promising targeted therapies. In clinical studies, increased response rates to tropomyosin receptor kinase inhibitors have been demonstrated in NTRK fusion-positive cancer types; however, real-world experiences on these targeted agents are scarce.ObjectiveWe evaluated the clinical characteristics and treatment responses of NTRK fusion-positive patients who received entrectinib treatment within the scope of an early access program in Turkey.Patients and methodsThis multicenter, retrospective analysis involved 17 patients with solid tumors harboring NTRK fusions or rearrangements from 14 oncology centers between June 2019 and 31 March 2024. Demographic and clinical data were obtained via retrospective review of medical records with a cutoff date of 31 March 2024.ResultsThe median age at diagnosis of the patients in our study was 42 [interquartile range (IQR) 33-60] years. Nine different types of solid tumors were diagnosed in these patients. The most common NTRK gene rearrangements involved NTRK1 (n = 8), followed by NTRK3 (n = 7). The median duration of entrectinib usage was 6.9 (IQR 3.1-16.1) months. Dose reductions due to side effects were performed in four patients: two due to leukopenia, one due to visual disturbance, and one due to troponin elevation. Leukopenia was the most commonly observed side effect. The objective response rate (ORR) was 35.3% (95% confidence interval (CI) 14.2-62.7), with complete response (CR) achieved in four patients. The duration of response (DOR) in patients who responded after initiating entrectinib was 9.8 (95% CI 0-30.7) months, the median overall survival (mOS) in all patients was 20.8 (95% CI 0-48.5) months, and the time-to-treatment failure (TTF) was 6.4 (95% CI 0-13.5) months.ConclusionsIn this retrospective study, we aimed to obtain real-world data concerning the use of entrectinib in patients with solid tumors harboring NTRK fusion genes. Although our findings are partially similar to the results of clinical studies, prospective studies in larger patient groups with more diverse tumor types and different demographic characteristics are needed to confirm the findings.
URI: https://doi.org/10.1007/s11523-024-01095-4
https://hdl.handle.net/11499/58057
ISSN: 1776-2596
1776-260X
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.